JP2005515210A5 - - Google Patents

Download PDF

Info

Publication number
JP2005515210A5
JP2005515210A5 JP2003552293A JP2003552293A JP2005515210A5 JP 2005515210 A5 JP2005515210 A5 JP 2005515210A5 JP 2003552293 A JP2003552293 A JP 2003552293A JP 2003552293 A JP2003552293 A JP 2003552293A JP 2005515210 A5 JP2005515210 A5 JP 2005515210A5
Authority
JP
Japan
Prior art keywords
och
ring
membered
membered saturated
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003552293A
Other languages
English (en)
Other versions
JP2005515210A (ja
JP4361798B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/013905 external-priority patent/WO2003051360A1/en
Publication of JP2005515210A publication Critical patent/JP2005515210A/ja
Publication of JP2005515210A5 publication Critical patent/JP2005515210A5/ja
Application granted granted Critical
Publication of JP4361798B2 publication Critical patent/JP4361798B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

Z1, Z2又はZ3の１つは-Hであり、そして他の２つは、それらが置換されているベンゼン環からの２つの炭素原子及びそれらの間の結合と共に、S、N、及びOから選択された少なくとも１つのヘテロ原子を含む５−及び６−員の飽和環並びに５−及び６−員の不飽和環から選択された環を形成し、ここで
R1は、-F, -OCH3, -N(CH3)2, 及びS, N及びOから選択された少なくとも１つのヘテロ原子を含む不飽和５−員の環から選択され、
R2は、３−〜６−員の飽和環であり、そして
Y1及びY2は、-Cl, -Br, -NO2, -CN及び-CCHからそれぞれ独立して選択される］で表される化合物、及び医薬的に許容できるその塩及びエステルから選択された、少なくとも１つの化合物を提供する。
［式中、Z1, Z2及びZ3は、C1-C6アルコキシ、-CH2OCH3及び-CH2OCH2CH3からそれぞれ独立して選択されるか、あるいはZ1, Z2又はZ3の１つは-Hであり、そして他の２つは、C1-C6アルキル、C1-C6アルコキシ、-Cl、-Br、-F、-CF3、 -CH20CH3、-CH20CH2CH3、-OCH2CH2Rl、-CH2-モルホリノ、-OR2、-CH2R2、 -OCH2CF3、-OCH(CH3)CH20H 及び-COOQからそれぞれ独立して選択され、ここでQは-H及びC1-C6アルキルから選択され、又は
Z1, Z2又はZ3の１つは-Hであり、そして他の２つは、それらが置換されているベンゼン環からの２つの炭素原子及びそれらの間の結合と共に、S、N、及びOから選択された少なくとも１つのヘテロ原子を含む５−及び６−員の飽和環並びに５−及び６−員の不飽和環から選択された環を形成し、ここで
JP2003552293A 2001-12-18 2002-12-09 Ｍｄｍ２インヒビターとしてのシス−イミダゾリン Expired - Fee Related JP4361798B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34172901P 2001-12-18 2001-12-18
US39087602P 2002-06-21 2002-06-21
PCT/EP2002/013905 WO2003051360A1 (en) 2001-12-18 2002-12-09 Cis-imidazolines as mdm2 inhibitors

Publications (3)

Publication Number Publication Date
JP2005515210A JP2005515210A (ja) 2005-05-26
JP2005515210A5 true JP2005515210A5 (ja) 2009-07-23
JP4361798B2 JP4361798B2 (ja) 2009-11-11

Family

ID=26992633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003552293A Expired - Fee Related JP4361798B2 (ja) 2001-12-18 2002-12-09 Ｍｄｍ２インヒビターとしてのシス−イミダゾリン

Country Status (20)

Country Link
US (1) US6617346B1 (ja)
EP (1) EP1463501B1 (ja)
JP (1) JP4361798B2 (ja)
KR (1) KR100640707B1 (ja)
CN (1) CN1604778A (ja)
AR (1) AR037882A1 (ja)
AT (1) ATE397925T1 (ja)
AU (1) AU2002361986B2 (ja)
BR (1) BR0215156A (ja)
CA (1) CA2468783A1 (ja)
DE (1) DE60227108D1 (ja)
ES (1) ES2307822T3 (ja)
MX (1) MXPA04005880A (ja)
PA (1) PA8561801A1 (ja)
PE (1) PE20030717A1 (ja)
PL (1) PL370909A1 (ja)
RU (1) RU2312101C2 (ja)
TW (1) TW200301696A (ja)
UY (1) UY27586A1 (ja)
WO (1) WO2003051360A1 (ja)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
MXPA05013465A (es) * 2003-06-17 2006-03-09 Hoffmann La Roche Cis-imidazolinas como inhibidores de mdm2.
KR20080027969A (ko) * 2004-05-18 2008-03-28 에프. 호프만-라 로슈 아게 신규 ｃｉｓ-이미다졸린
EP1758579A1 (en) * 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for medicinal uses
US7893278B2 (en) * 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
US7759383B2 (en) 2005-02-22 2010-07-20 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
AU2006216780B8 (en) * 2005-02-22 2010-04-22 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and uses thereof
CN101316823B (zh) 2005-12-01 2013-05-22 霍夫曼-拉罗奇有限公司 用作抗癌剂的作为p53和MDM2蛋白之间相互作用的抑制剂的2,4,5-三苯基咪唑啉衍生物
BRPI0710477A2 (pt) * 2006-01-18 2011-08-16 Hoffmann La Roche cis-4, 5- biarila - 2- imidazolinas heterocìclicas como inibidores da mdm2
WO2008014216A1 (en) 2006-07-28 2008-01-31 St. Jude Children's Research Hospital Method for treating ocular cancer
US8470785B2 (en) 2006-07-28 2013-06-25 St. Jude Children's Research Hospital Method for treating ocular cancer
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
CN101605798A (zh) 2006-12-14 2009-12-16 第一三共株式会社 咪唑并噻唑衍生物
US7625895B2 (en) * 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2009047161A1 (en) * 2007-10-09 2009-04-16 F. Hoffmann-La Roche Ag Chiral cis-imidazolines
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
JPWO2009151069A1 (ja) 2008-06-12 2011-11-17 第一三共株式会社 ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
ES2463820T3 (es) 2009-01-16 2014-05-29 Daiichi Sankyo Company, Limited Derivado de imidazotiazol que tiene estructura de anillo de prolina
CN104876938A (zh) 2009-11-12 2015-09-02 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
US10159669B2 (en) * 2010-03-02 2018-12-25 Ian H. Chan Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
US20130225603A1 (en) * 2010-09-27 2013-08-29 Serrata Llc Mdm2 inhibitors for treatment of ocular conditions
WO2012045018A1 (en) 2010-09-30 2012-04-05 St. Jude Children's Research Hospital Aryl-substituted imidazoles
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
PE20140408A1 (es) 2010-11-12 2014-04-10 Univ Michigan Derivados espiro-oxindol como antagonistas de mdm2
TR201807311T4 (tr) 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
MX346375B (es) 2011-05-11 2017-03-16 Univ Michigan Regents Antagonistas de espiro-oxindol de mdm2.
KR101384683B1 (ko) * 2011-10-27 2014-04-11 한국생명공학연구원 ｍｄｍ２－결합 모티프를 포함하는 펩타이드 및 이의 용도
US9937178B2 (en) 2011-12-07 2018-04-10 Duke University Methods of identifying and using MDM2 inhibitors
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
TWI750129B (zh) * 2015-08-03 2021-12-21 瑞士商諾華公司 作為血液學毒性生物標記之ｇｄｆ-１５
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
SG11201911909UA (en) 2017-06-16 2020-01-30 Unity Biotechnology Inc Synthesis method for producing enantiomerically pure cis-imidazoline compounds for pharmaceutical use
WO2019195851A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
BR112021006647A2 (pt) 2018-10-08 2021-07-13 The Regents Of The University Of Michigan degradores de proteína mdm2 de pequenas moléculas
WO2021188948A1 (en) 2020-03-19 2021-09-23 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
WO2022183006A1 (en) 2021-02-25 2022-09-01 Mayo Foundation For Medical Education And Research Compounds for programmable protein degradation and methods of use for the disease treatment
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR75287B (ja) * 1980-07-25 1984-07-13 Ciba Geigy Ag
JPH02101065A (ja) * 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
WO1992003421A2 (en) 1990-08-17 1992-03-05 E.I. Du Pont De Nemours And Company Arthropodicidal pyrazolines, pyrazolidines and hydrazines
GB2351082A (en) * 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines

Similar Documents

Publication Publication Date Title
EA200300305A1 (ru) Альфа-арилэтаноламины и их применение в качестве агонистов бета-адренергических рецепторов
AR037882A1 (es) Cis-imidazolinas
AU2003217274A1 (en) Peroxisome proliferator activated receptor modulators
TW346485B (en) Substituted N-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents
EA200600348A1 (ru) Новые соединения
NO20060220L (no) Forbindelser med inhiberene aktivitet mot natriumavhengige transportorer
MY149463A (en) Novel compounds
AR038762A1 (es) Derivados de indolina, un proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion y el uso de dichos derivados para la fabricacion de un medicamento
CA2249542A1 (en) Pyrazole derivatives, their preparation and their use in pharmaceuticals
JP2006523698A5 (ja)
IL185199A (en) Indole compounds and medications containing them for the prevention of and / or treatment of leucotriene colton disease
RU2394028C2 (ru) Производные бензилтриазолона в качестве ненуклеозидных ингибиторов обратной транскриптазы
WO2003024441A1 (en) Novel use of tricyclic compound
JP2005525392A5 (ja)
JP2008520811A5 (ja)
WO2003048130A3 (en) Peroxisome proliferator activated receptor agonists
CA2169737A1 (en) Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
JP2001525394A5 (ja)
JP2005525364A5 (ja)
AR044869A1 (es) Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion
EA200500240A1 (ru) Новый способ синтеза соединений 1,3,4,5-тетрагидро-2h-3-бензазепин-2-она и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
DE69120603D1 (de) Isochromanderivate
EA200200973A1 (ru) Пиридазинилфенилгидразоны, применяемые при застойной сердечной недостаточности
DE602004024584D1 (de) Inhibitoren der nicht-nukleotidischen reversen transkriptase
JP2024037892A5 (ja)